{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:23:38Z","timestamp":1791822218863,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neurot.2025.e00568","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:20:29Z","timestamp":1741296029000},"page":"e00568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X"],"prefix":"10.1016","volume":"22","author":[{"given":"Melina","family":"Christou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sargiannidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revekka","family":"Papacharalambous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tryfonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Kagiava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleopas A.","family":"Kleopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 5","key":"10.1016\/j.neurot.2025.e00568_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/brain\/113.5.1511","article-title":"X-linked dominant hereditary motor and sensory neuropathy","volume":"113","author":"Hahn","year":"1990","journal-title":"Brain: J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00568_bib2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/WNL.50.4.1074","article-title":"X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study","volume":"50","author":"Birouk","year":"1998","journal-title":"Neurology"},{"issue":"Pt 10","key":"10.1016\/j.neurot.2025.e00568_bib3","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1093\/brain\/124.10.1958","article-title":"Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease","volume":"124","author":"Dubourg","year":"2001","journal-title":"Brain: J Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00568_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/jnnp-2014-308826","article-title":"CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis","volume":"86","author":"Fridman","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00568_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/NMM:8:1-2:107","article-title":"Molecular genetics of X-linked Charcot-Marie-Tooth disease","volume":"8","author":"Kleopa","year":"2006","journal-title":"NeuroMolecular Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00568_bib6","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1523\/JNEUROSCI.15-12-08281.1995","article-title":"Connexin32 is a myelin-related protein in the PNS and CNS","volume":"15","author":"Scherer","year":"1995","journal-title":"J\u00a0Neurosci : the official journal of the Society for Neuroscience"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00568_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1083\/jcb.142.4.1095","article-title":"Functional gap junctions in the schwann cell myelin sheath","volume":"142","author":"Balice-Gordon","year":"1998","journal-title":"J\u00a0Cell Biol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00568_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1529-8027.2011.00321.x","article-title":"A\u00a0novel mutation in the nerve-specific 5'UTR of the GJB1 gene causes X-linked Charcot-Marie-Tooth disease","volume":"16","author":"Murphy","year":"2011","journal-title":"J\u00a0Peripher Nerv Syst: JPNS."},{"issue":"15","key":"10.1016\/j.neurot.2025.e00568_bib9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1212\/WNL.0000000000003819","article-title":"Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT","volume":"88","author":"Tomaselli","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00568_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1091\/mbc.7.6.907","article-title":"Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects","volume":"7","author":"Omori","year":"1996","journal-title":"Mol Biol Cell"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/(SICI)1097-4547(19980115)51:2<154::AID-JNR4>3.0.CO;2-C","article-title":"Mutations of connexin32 in Charcot-Marie-Tooth disease type X interfere with cell-to-cell communication but not cell proliferation and myelin-specific gene expression","volume":"51","author":"Yoshimura","year":"1998","journal-title":"J\u00a0Neurosci Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00568_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/nbdi.2002.0545","article-title":"Diverse trafficking abnormalities of connexin32 mutants causing CMTX","volume":"11","author":"Yum","year":"2002","journal-title":"Neurobiol Dis"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00568_bib13","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1523\/JNEUROSCI.17-23-09077.1997","article-title":"Altered trafficking of mutant connexin32","volume":"17","author":"Deschenes","year":"1997","journal-title":"J\u00a0Neurosci: the official journal of the Society for Neuroscience"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1471-4159.2000.740711.x","article-title":"Analysis of gap junction assembly using mutated connexins detected in Charcot-Marie-Tooth X-linked disease","volume":"74","author":"Martin","year":"2000","journal-title":"J\u00a0Neurochem"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00568_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0896-6273(00)80973-3","article-title":"Changes in permeability caused by connexin 32 mutations underlie X-linked Charcot-Marie-Tooth disease","volume":"19","author":"Oh","year":"1997","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00568_bib16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/hmg\/ddy056","article-title":"Intrathecal gene therapy in mouse models expressing CMT1X mutations","volume":"27","author":"Kagiava","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00568_bib17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/hmg\/ddz199","article-title":"Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X","volume":"28","author":"Kagiava","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00568_bib18","doi-asserted-by":"crossref","first-page":"E2421","DOI":"10.1073\/pnas.1522202113","article-title":"Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy","volume":"113","author":"Kagiava","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.24441","article-title":"Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease","volume":"78","author":"Sargiannidou","year":"2015","journal-title":"Ann Neurol"},{"issue":"10-11","key":"10.1016\/j.neurot.2025.e00568_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41434-021-00250-0","article-title":"AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy","volume":"28","author":"Kagiava","year":"2021","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00568_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02694-1","article-title":"Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery","volume":"11","author":"Kagiava","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00568_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2023.07.011","article-title":"Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy","volume":"30","author":"Kagiava","year":"2023","journal-title":"Molecular therapy Methods & clinical development"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00568_bib23","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J\u00a0Virol"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00568_bib24","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.neurot.2025.e00568_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral immune response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00568_bib26","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1016\/j.ymthe.2023.08.020","article-title":"AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C","volume":"31","author":"Georgiou","year":"2023","journal-title":"Mol Ther: the journal of the American Society of Gene Therapy"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500078","article-title":"Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model","volume":"1","author":"Nizzardo","year":"2015","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00568_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/mt.2016.33","article-title":"Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent","volume":"24","author":"Shababi","year":"2016","journal-title":"Mol Ther: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.neurot.2025.e00568_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Molecular therapy Methods & clinical development"},{"key":"10.1016\/j.neurot.2025.e00568_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2025.e00568_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/mtm.2013.7","article-title":"Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy","volume":"1","author":"Homs","year":"2014","journal-title":"Molecular therapy Methods & clinical development"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00568_bib32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jnr.23882","article-title":"Intrathecal administration of AAV\/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant","volume":"94","author":"Karumuthil-Melethil","year":"2016","journal-title":"J\u00a0Neurosci Res"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00568_bib33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/hum.2017.151","article-title":"AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease)","volume":"29","author":"Bradbury","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib34","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2016.102","article-title":"Inexpensive, serotype-independent protocol for native and bioengineered recombinant adeno-associated virus purification","volume":"3","author":"Arden","year":"2016","journal-title":"Journal of biological methods"},{"key":"10.1016\/j.neurot.2025.e00568_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1472-6750-6-34","article-title":"Comparison of lentiviral vector titration methods","volume":"6","author":"Geraerts","year":"2006","journal-title":"BMC Biotechnol"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00568_bib36","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1073\/pnas.93.18.9565","article-title":"Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice","volume":"93","author":"Nelles","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00568_bib37","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1523\/JNEUROSCI.0325-09.2009","article-title":"Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects","volume":"29","author":"Sargiannidou","year":"2009","journal-title":"J\u00a0Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00568_bib38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/NEN.0b013e3181efa658","article-title":"Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating\/type I Charcot-Marie Tooth neuropathy","volume":"69","author":"Vavlitou","year":"2010","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00568_bib39","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1093\/hmg\/ddq269","article-title":"Attenuation of MCP-1\/CCL2 expression ameliorates neuropathy in a mouse model for Charcot-Marie-Tooth 1X","volume":"19","author":"Groh","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"Pt 4","key":"10.1016\/j.neurot.2025.e00568_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/brain\/awg072","article-title":"Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1","volume":"126","author":"Kobsar","year":"2003","journal-title":"Brain: J Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00568_bib41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurot.2025.e00568_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12974-015-0267-y","article-title":"Endogenous antibodies contribute to macrophage-mediated demyelination in a mouse model for CMT1B","volume":"12","author":"Klein","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.neurot.2025.e00568_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113272","article-title":"Biology of the human blood-nerve barrier in health and disease","volume":"328","author":"Ubogu","year":"2020","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2025.e00568_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Molecular therapy Methods & clinical development"},{"key":"10.1016\/j.neurot.2025.e00568_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing iduronate-2-sulfatase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Molecular therapy Methods & clinical development"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00568_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"15-16","key":"10.1016\/j.neurot.2025.e00568_bib47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2131\/jts.46.57","article-title":"Development challenges associated with rAAV-based gene therapies","volume":"46","author":"Bolt","year":"2021","journal-title":"J\u00a0Toxicol Sci"},{"key":"10.1016\/j.neurot.2025.e00568_bib49","series-title":"EMA. Zolgensma: assessment report","year":"2020"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00568_bib51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","article-title":"AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy","volume":"22","author":"Thwaite","year":"2015","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00568_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198154","article-title":"Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation","volume":"13","author":"Ramsingh","year":"2018","journal-title":"PLoS One"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:26:42Z","timestamp":1744723602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1878747925000467"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00568","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00568"}}